Onclive today, 12/14/12...titled as above...Dr Konner on Cabo's promise in OC...
"Other agents have also shown promising data. Cabozantinib, an oral tyrosine kinase inhibitor (TKI) that recently became FDA-approved to treat medullary thyroid cancer, is being investigated in a number of additional tumor types, including ovarian cancer. “That’s probably the most promising oral TKI for ovarian cancer, having shown the most pronounced response rates in early trials,” Konner said.
The results of a phase II randomized discontinuation trial examining cabozantinib in advanced ovarian cancer were presented at the 2011 ASCO Annual Meeting. The study was halted because a high rate of clinical activity was observed. The overall response rate among patients with progressive measurable disease at 12 weeks was 24%, and clinical activity was observed regardless of whether patients had previously been treated with platinum-based therapy (J Clin Oncol. 2011;29[suppl; abstr 5008]). A randomized phase II trial has been designed to compare cabozantinib with paclitaxel in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer."
Ovarian cancer is the second most common gynecologic cancer and the deadliest in terms of absolute figure. It caused nearly 14,000 deaths in the United States alone in 2010. Global ovarian cancer drugs market to reach $2,352 million.